1. The Use of Electronic Medical Records-Based Big-Data Informatics to Describe ALT Elevations Higher than 1000 IU/L in Patients with or without Hepatitis B Virus Infection
- Author
-
Hiroyuki Amano, Tatsuo Kanda, Hitoshi Mochizuki, Yuichiro Kojima, Yoji Suzuki, Kenji Hosoda, Hiroshi Ashizawa, Yuko Miura, Shotaro Tsunoda, Yosuke Hirotsu, Hiroshi Ohyama, Naoya Kato, Mitsuhiko Moriyama, Shuntaro Obi, and Masao Omata
- Subjects
ACLF ,acute liver failure ,ALT elevation ,HBV reactivation ,HBV surface antigen ,Microbiology ,QR1-502 - Abstract
Hepatitis B virus (HBV) infection is one of the serious health problems in the world as HBV causes severe liver diseases. Moreover, HBV reactivation has occasionally been observed in patients with resolved HBV infection and patients using immunosuppression and anticancer drugs. Large-scale hospital data focused on HBV infection and severe liver function were analyzed at our hospital, located in an urban area adjacent to Tokyo, the capital city of Japan. A total of 99,932 individuals whose blood samples were taken at 7,170,240 opportunities were analyzed. The HBV surface antigen (HBsAg)-positive group had a more frequent prevalence of patients with higher transaminase elevations than the HBsAg-negative group. However, among the HBsAg-negative group, patients who were positive for anti-HBV surface antibody and/or anti-HBV core antibody, had more severe liver conditions and fatal outcomes. More careful attention should be paid to alanine transaminase (ALT) elevations higher than 1000 IU/L in patients who had current and previous HBV infection.
- Published
- 2021
- Full Text
- View/download PDF